Cavit Sciences, Inc. Announces Update to Shareholders

PATERSON, NJ--(Marketwire - January 27, 2009) - Cavit Sciences, Inc. (“Cavit”) (OTCBB: CVIT) announced today the following update to its shareholders:

To: Shareholders of Cavit Sciences Inc.

From: Maggie Smyth, Interim CEO

Shareholders update:

We have been informed that our first Purchase Order will be delivered earlier than expected, and that our website will be ready for our January 30th meeting in Virginia with our marketing group and design crew, with this news we have been able to move the launch date of our Supplement Line and Website to February 15th.

We have signed a consulting and development agreement with Dr. Joseph Mix who will be helping with our vision for the optimal product and the direction of our Supplement Line. We are hopeful Dr. Mix will be the first of many Doctors and Advisors to our company as we grow.

We have also engaged the services of “Internet Marketing Communications” to help with the marketing of our product line along with literature, videos and teleconferencing calls.

We are looking to add 1 or 2 new products, along with our research and published journals every few months, economy permitting.

We will continually reevaluate our supplements as new and tested information comes our way.

Unfortunately our company’s past management is refusing to turn over books and ledgers. We will diligently work at rectifying this situation, but are confident this will not alter the company from moving forward.

In regards to information we requested from past management about our products, we have not received any response. We were informed that the company had 15 supplement formulas ready to go, but so far we have only located 5 in the files sent to us. This was confirmed by the manufacturer, but through the work and commitment of present management and advisors we will formulate future products in the months ahead.

Our main concern is to become an income producing company, after that, the BOD will sit down and decide what to do about the return of Cavit’s property and reimbursement of money and shares.

Our long-term plan is to turn our company into a mini Berkshire Hathaway model with a percentage of every quarters profits going to investing in brand-name companies we consider to be undervalued, our own stock buyback or a return to the shareholders. We vow to not repeat the previous practices of past management.

We have a lot ahead of us, but we feel with the right people we now have on our team, and a solid business plan, we will be successful.

Cavit Sciences, Inc. (“Cavit”) is a biotechnology company engaged in developing treatments and prevention for cancer, viral infections and related diseases along with supplements for the growing population. Additional information regarding our drug development, supplement line and Company information is available on the Company’s website at: www.cavitsciences.com.

Statements contained herein that are not historical fact may be orward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, and (ii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit’s filings with the Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” for Cavit on Form 10-K filed on April 18, 2008 and its subsequently filed Forms 10-Q.